Overview

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Status:
Active, not recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

To determine the rate of disease control of the combination of 9-ING-41 and retifanlimab plus gemcitabine/nab-paclitaxel in patients with pancreatic cancer without prior systemic therapy for advanced disease. The researchers will be looking at how the cancer you have reacts to the addition of 9-ING-41 and retifanlimab to the standard of care chemotherapy treatment. They want to discover if using this combination will help and is able to keep the cancer you have from progressing.

Phase:

Phase 2

Details

Lead Sponsor:

University of Kansas Medical Center

Collaborators:

Actuate Therapeutics Inc.
Incyte Corporation

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine